Evidence map›Paper›PMID 42506625›Full record

ArticleVaccines2026

Implementation of a Large-Scale Ebola Vaccination Campaign in Rwanda.

Rosine Ingabire, Julien Nyombayire, Felix Sayinzoga, Jean Baptiste Mazarati, Amelia Mazzei, Karel Van Roey, Moses Kasigazi, Placide Nshizirungu, Oreste Tuganeyezu, Sabin Nsanzimana and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Rosine IngabireCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Julien NyombayireCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Felix SayinzogaRwanda Biomedical Center, Kigali P.O. Box 7162, Rwanda.
Jean Baptiste MazaratiRwanda Biomedical Center, Kigali P.O. Box 7162, Rwanda.
Amelia MazzeiCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Karel Van RoeyJanssen R&D, 2340 Beerse, Belgium.
Moses KasigaziCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Placide NshizirunguGihundwe District Hospital, Rusizi P.O. Box 87, Rwanda.
Oreste TuganeyezuGisenyi District Hospital, Rubavu P.O. Box 175, Rwanda.
Sabin NsanzimanaRwanda Ministry of Health, Kigali P.O. Box 84, Rwanda.
Chantal SifaCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Japhet NiyonzimaCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Edouard MirimoCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.
Paula Mc KennaJanssen R&D, 2340 Beerse, Belgium.
Rachel ParkerRwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Amanda TichacekRwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.
Jozef NobenJanssen R&D, 2340 Beerse, Belgium.
Kristin M WallRwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0001-8547-2004
Susan AllenRwanda Zambia Health Research Group, Department of Pathology and Laboratory Medicine, School of Medicine, Emory University, Atlanta, GA 30322, USA.ORCID 0000-0002-9150-3898
Etienne KaritaCenter for Family Health Research, Kigali P.O. Box 780, Rwanda.ORCID 0000-0001-9475-5436

Funding

Janssen Vaccines and Prevention B.V. Not applicableJohnson & Johnson Not applicableJohnson & Johnson Global Public Health Team Not applicableWELLCOME (formerly Wellcome Trust) / United Kingdom Foreign, Commonwealth and Development Office (formerly the UK Department for International Development Not applicableWellcome Trust
6 · The paper itself

Abstract

BACKGROUND/

objectivesEbola Virus Disease (EVD) remains a public health threat in sub-Saharan Africa. The 10th Ebola outbreak in the Democratic Republic of the Congo (DRC) in 2018-2020 led the Rwanda Ministry of Health to launch a large-scale Ebola vaccination campaign using the two-dose Ad26.ZEBOV and MVA-BN-Filo regimen. The campaign was implemented by local organizations, the Center for Family Health Research and Rinda Ubuzima, in partnership with the Rwanda Biomedical Center.

methodsThe campaign targeted those who live near or routinely cross the Rwanda/DRC border and unvaccinated first responders. Children <2 years and pregnant women were excluded.

resultsBetween December 2019 and September 2021, 219,775 individuals attended vaccination sites and 216,108 received the first dose. Of those, 110,699 (51.2%) were adults (≥18 years) and 105,409 (48.8%) were children aged 2-17 years. A total of 118,048 (54.6%) were women and 98,060 (45.4%) were men. Of all first-dose clients, 203,303 (94.1%) received the second dose. Participants who were older, male, in Rubavu district, and urban were more likely (

conclusionsFindings highlight that a large-scale vaccination campaign, including remote areas, is feasible with high adherence despite the concurrent COVID-19 pandemic. Early stakeholder engagement and local leadership were critical to success. Future studies of reasons for non-adherence, as well as strategies to integrate family planning into campaign activities to reduce ineligibility due to pregnancy, are warranted.

Indexed as

EbolaEbola hemorrhagic feverEbola vaccineEbola virusEbola virus vaccinelarge-scale vaccinationmass immunizationmass vaccinationRwanda

Identifiers

PMID42506625
PMCPMC13416593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.